Projects

Librexia AF is a randomized study to evaluate the efficacy and safety of mlivexian versus apixaban in atrial fibrillation.

Project Description

Librexia AF is a randomized, double-blind, double-dummy, parallel group, active-controlled study to evaluate the efficacy and safety of milvexian versus apixaban in participants with atrial fibrillation. Librexia AF is a randomized, double-blind, double-dummy, parallel group, active-controlled study to evaluate the efficacy and safety of milvexian versus apixaban in participants with atrial fibrillation.Librexia AF is a randomized, double-blind, double-dummy, parallel group, active-controlled study to evaluate the efficacy and safety of milvexian versus apixaban in participants with atrial fibrillation.

Project Duration

2024 - Ongoing

Project Lead

National Leader: Dr Denis Xavier

Authors

Dr E. Tan

Project Status

completed

Project Type

Type 1